Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: A case report

Miriam Galbusera, Elena Bresin, Marina Noris, Sara Gastoldi, Daniela Belotti, Cristina Capoferri, Erica Daina, Paolo Perseghin, Friedrich Scheiflinger, Fadi Fakhouri, Jean Pierre Grünfeld, Enrico Pogliani, Giuseppe Remuzzi

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a rare disorder of small vessels that is associated with deficiency of the von Willebrand factor-cleaving protease, ADAMTS13. The presence of anti-ADAMTS13 autoantibodies is considered a factor predisposing to relapses, Despite close monitoring and intensive plasma treatment, in these patients acute episodes are still associated with substantial morbidity and mortality rates, and the optimal therapeutic option should be prevention of relapses. This study was conducted in a patient with recurrent TTP due to high titers of ADAMTS13 inhibitors, who used to have 2 relapses of TTP a year. The study compared the standard treatment plasma exchange with rituximab. Results documented that plasma exchange had only a small transient effect on ADAMTS13 activity and inhibitors; on the contrary, prophylaxis with rituximab was associated with disappearance of anti-ADAMTS13 antibodies, a progressive recovery of protease activity, and it allowed the patient to maintain a disease-free state during a more than 2-year follow-up.

Original languageEnglish
Pages (from-to)925-928
Number of pages4
JournalBlood
Volume106
Issue number3
DOIs
Publication statusPublished - Aug 1 2005

Fingerprint

Thrombotic Thrombocytopenic Purpura
Plasma Exchange
Plasmas
Recurrence
Peptide Hydrolases
von Willebrand Factor
Secondary Prevention
Causality
Autoantibodies
Anti-Idiotypic Antibodies
Therapeutics
Morbidity
Recovery
Mortality
Antibodies
Monitoring
Rituximab

ASJC Scopus subject areas

  • Hematology

Cite this

Rituximab prevents recurrence of thrombotic thrombocytopenic purpura : A case report. / Galbusera, Miriam; Bresin, Elena; Noris, Marina; Gastoldi, Sara; Belotti, Daniela; Capoferri, Cristina; Daina, Erica; Perseghin, Paolo; Scheiflinger, Friedrich; Fakhouri, Fadi; Grünfeld, Jean Pierre; Pogliani, Enrico; Remuzzi, Giuseppe.

In: Blood, Vol. 106, No. 3, 01.08.2005, p. 925-928.

Research output: Contribution to journalArticle

Galbusera, M, Bresin, E, Noris, M, Gastoldi, S, Belotti, D, Capoferri, C, Daina, E, Perseghin, P, Scheiflinger, F, Fakhouri, F, Grünfeld, JP, Pogliani, E & Remuzzi, G 2005, 'Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: A case report', Blood, vol. 106, no. 3, pp. 925-928. https://doi.org/10.1182/blood-2004-12-4885
Galbusera, Miriam ; Bresin, Elena ; Noris, Marina ; Gastoldi, Sara ; Belotti, Daniela ; Capoferri, Cristina ; Daina, Erica ; Perseghin, Paolo ; Scheiflinger, Friedrich ; Fakhouri, Fadi ; Grünfeld, Jean Pierre ; Pogliani, Enrico ; Remuzzi, Giuseppe. / Rituximab prevents recurrence of thrombotic thrombocytopenic purpura : A case report. In: Blood. 2005 ; Vol. 106, No. 3. pp. 925-928.
@article{112cafef38be48c09ac5115fece37bf0,
title = "Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: A case report",
abstract = "Thrombotic thrombocytopenic purpura (TTP) is a rare disorder of small vessels that is associated with deficiency of the von Willebrand factor-cleaving protease, ADAMTS13. The presence of anti-ADAMTS13 autoantibodies is considered a factor predisposing to relapses, Despite close monitoring and intensive plasma treatment, in these patients acute episodes are still associated with substantial morbidity and mortality rates, and the optimal therapeutic option should be prevention of relapses. This study was conducted in a patient with recurrent TTP due to high titers of ADAMTS13 inhibitors, who used to have 2 relapses of TTP a year. The study compared the standard treatment plasma exchange with rituximab. Results documented that plasma exchange had only a small transient effect on ADAMTS13 activity and inhibitors; on the contrary, prophylaxis with rituximab was associated with disappearance of anti-ADAMTS13 antibodies, a progressive recovery of protease activity, and it allowed the patient to maintain a disease-free state during a more than 2-year follow-up.",
author = "Miriam Galbusera and Elena Bresin and Marina Noris and Sara Gastoldi and Daniela Belotti and Cristina Capoferri and Erica Daina and Paolo Perseghin and Friedrich Scheiflinger and Fadi Fakhouri and Gr{\"u}nfeld, {Jean Pierre} and Enrico Pogliani and Giuseppe Remuzzi",
year = "2005",
month = "8",
day = "1",
doi = "10.1182/blood-2004-12-4885",
language = "English",
volume = "106",
pages = "925--928",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Rituximab prevents recurrence of thrombotic thrombocytopenic purpura

T2 - A case report

AU - Galbusera, Miriam

AU - Bresin, Elena

AU - Noris, Marina

AU - Gastoldi, Sara

AU - Belotti, Daniela

AU - Capoferri, Cristina

AU - Daina, Erica

AU - Perseghin, Paolo

AU - Scheiflinger, Friedrich

AU - Fakhouri, Fadi

AU - Grünfeld, Jean Pierre

AU - Pogliani, Enrico

AU - Remuzzi, Giuseppe

PY - 2005/8/1

Y1 - 2005/8/1

N2 - Thrombotic thrombocytopenic purpura (TTP) is a rare disorder of small vessels that is associated with deficiency of the von Willebrand factor-cleaving protease, ADAMTS13. The presence of anti-ADAMTS13 autoantibodies is considered a factor predisposing to relapses, Despite close monitoring and intensive plasma treatment, in these patients acute episodes are still associated with substantial morbidity and mortality rates, and the optimal therapeutic option should be prevention of relapses. This study was conducted in a patient with recurrent TTP due to high titers of ADAMTS13 inhibitors, who used to have 2 relapses of TTP a year. The study compared the standard treatment plasma exchange with rituximab. Results documented that plasma exchange had only a small transient effect on ADAMTS13 activity and inhibitors; on the contrary, prophylaxis with rituximab was associated with disappearance of anti-ADAMTS13 antibodies, a progressive recovery of protease activity, and it allowed the patient to maintain a disease-free state during a more than 2-year follow-up.

AB - Thrombotic thrombocytopenic purpura (TTP) is a rare disorder of small vessels that is associated with deficiency of the von Willebrand factor-cleaving protease, ADAMTS13. The presence of anti-ADAMTS13 autoantibodies is considered a factor predisposing to relapses, Despite close monitoring and intensive plasma treatment, in these patients acute episodes are still associated with substantial morbidity and mortality rates, and the optimal therapeutic option should be prevention of relapses. This study was conducted in a patient with recurrent TTP due to high titers of ADAMTS13 inhibitors, who used to have 2 relapses of TTP a year. The study compared the standard treatment plasma exchange with rituximab. Results documented that plasma exchange had only a small transient effect on ADAMTS13 activity and inhibitors; on the contrary, prophylaxis with rituximab was associated with disappearance of anti-ADAMTS13 antibodies, a progressive recovery of protease activity, and it allowed the patient to maintain a disease-free state during a more than 2-year follow-up.

UR - http://www.scopus.com/inward/record.url?scp=23044433307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23044433307&partnerID=8YFLogxK

U2 - 10.1182/blood-2004-12-4885

DO - 10.1182/blood-2004-12-4885

M3 - Article

C2 - 15827129

AN - SCOPUS:23044433307

VL - 106

SP - 925

EP - 928

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -